PF-Atlas › Clinical Trials › NCT03633526
Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
VX-659/TEZ/IVA · Phase 3
Registry ID
NCT03633526
Phase
Phase 3
Status
Terminated
Drug / intervention
VX-659/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2018-08-03
Enrollment
18
Locations
6
About this trial
This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-659, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects with F/F or F/MF genotypes. The study was discontinued after completion of Part A due to Sponsor's discretion.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03633526 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.